XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue - Total Revenue by Category and by US versus Rest of World (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Disaggregation of Revenue [Line Items]        
Total revenue $ 179.3 $ 189.4 $ 344.2 $ 362.5
U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 157.5 164.9 299.2 319.6
RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 21.8 24.5 45.0 42.9
Molecular diagnostic testing        
Disaggregation of Revenue [Line Items]        
Total revenue 179.3 178.7 344.2 338.3
Molecular diagnostic testing | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 157.5 154.2 299.2 295.4
Molecular diagnostic testing | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 21.8 24.5 45.0 42.9
Hereditary Cancer        
Disaggregation of Revenue [Line Items]        
Total revenue 79.4 86.0 150.3 162.1
Hereditary Cancer | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 69.8 73.8 130.5 138.9
Hereditary Cancer | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 9.6 12.2 19.8 23.2
Tumor Profiling        
Disaggregation of Revenue [Line Items]        
Total revenue 33.5 30.3 66.0 61.5
Tumor Profiling | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 21.5 18.2 41.2 42.1
Tumor Profiling | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 12.0 12.1 24.8 19.4
Prenatal        
Disaggregation of Revenue [Line Items]        
Total revenue 33.3 29.4 65.2 53.1
Prenatal | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 33.1 29.2 64.8 52.8
Prenatal | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 0.2 0.2 0.4 0.3
Pharmacogenomics        
Disaggregation of Revenue [Line Items]        
Total revenue 33.1 22.6 62.4 40.2
Pharmacogenomics | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 33.1 22.6 62.4 40.2
Pharmacogenomics | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 0.0 0.0 0.0 0.0
Pharmacogenomics        
Disaggregation of Revenue [Line Items]        
Total revenue 0.0 10.2 0.3 20.9
Pharmacogenomics | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 0.0 10.2 0.3 20.9
Pharmacogenomics | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 0.0 0.0 0.0 0.0
Other        
Disaggregation of Revenue [Line Items]        
Total revenue 0.0 0.2 0.0 0.5
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 0.0 0.2 0.0 0.5
Other | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 0.0 0.0 0.0 0.0
Pharmaceutical and clinical services        
Disaggregation of Revenue [Line Items]        
Total revenue 0.0 10.7 0.0 24.2
Pharmaceutical and clinical services | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 0.0 10.7 0.0 24.2
Pharmaceutical and clinical services | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue $ 0.0 $ 0.0 $ 0.0 $ 0.0